Disitamab vedotin
- Generic Name
- Disitamab vedotin
- Drug Type
- Biotech
- CAS Number
- 2136633-23-1
- Unique Ingredient Identifier
- RB3U3A1S27
- Background
Disitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers.
- Indication
用于至少接受过2个系统化疗的HER2过表达局部晚期或转移性胃癌（包括胃食管结合部腺癌）的患者，HER2过表达定义为HER2免疫组织化学检查结果为2+或3+。
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
- Conditions
- Breast CancerBreast Neoplasms
- Interventions
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT06966453
Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
- Conditions
- Bladder CancerMuscle-invasive Bladder Cancer
- Interventions
- Drug: Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）Procedure: Radical Cystectomy with Pelvic Lymph Node Dissection
- First Posted Date
- 2025-05-04
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 30
- Registration Number
- NCT06957561
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Probiotics in Advanced Urothelial Carcinoma
- Conditions
- ProbioticsAdvanced Urothelial CarcinomaImmunotherapy
- Interventions
- Drug: Probiotics Compound (Biolosion)Drug: Enfortumab Vedotin
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 222
- Registration Number
- NCT06904573
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, China
🇨🇳Sun yat-sen university cancer center, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
- Conditions
- HER2-positive Gastric CancerMetastatic Gastric CancerUnresectable Gastric Carcinoma
- Interventions
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 110
- Registration Number
- NCT06730373
- Locations
- 🇨🇳
Shandong Univerisity Qilu Hospital, Jinan, Shandong, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Jinan Third People's Hospital, Jinan, Shandong, China
RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure
- Conditions
- Prostate CancerCDK12 Gene Mutation
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Tianjin Medical University Second Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT06663007
- Locations
- 🇨🇳
Tianjin Medical Unversity Second Hospital, Tianjin, Tianjin, China
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
- Conditions
- Metastatic HER2 Positive Gastroesophageal Junction Cancer
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT06650332
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06642545
- Locations
- 🇨🇳
Cance Hosoltal Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease.
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 36
- Registration Number
- NCT06561555
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer
- Conditions
- HER2-positive Gastric Cancer
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Target Recruit Count
- 20
- Registration Number
- NCT06492317
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 79
- Registration Number
- NCT06389006
- Locations
- 🇨🇳
Jiong Wu, Shanghai, Fudan University Shanghai Cancer Center, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.